Is One SGLT2 Or GLP1 Just Like Another for Cardiac Benefit

02 Jan, 2019 ,

The American College of Cardiology has issued an Expert Consensus Decision Pathway on the use of two major new classes of diabetes drugs SGLT2 inhibitors and GLP1 receptor agonists While intended for cardiologists who typically leave the glucose management to endocrinologists and primary care the document provides good information for all